Healthcare / Medical Instruments & SuppliesTel Aviv
$45.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-2.8M · quality 65.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5M
P/E
N/A
•EV/EBITDA
N/A
•ROE
209.0%
↑Gross Margin
N/A
•Debt/Equity
-0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.44x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-4.9M · FCF $-2.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-4.9M | $-4.9M | $-14.2M | $-8.6M | $-2.5M |
| EBITDA | $-4.8M | $-4.8M | $-14.2M | $-8.5M | $-2.5M |
| EPS | — | — | -1.95 | -1.19 | -0.38 |
| Balance Sheet | |||||
| Debt/Equity | -0.09 | -0.09 | — | — | — |
| Current Ratio | 0.05 | 0.05 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.2M | $-2.2M | $-4.4M | $-2.8M | $-3.2M |
| Returns | |||||
| ROE | 209.0% | 209.0% | 1650.2% | -69.3% | -12.3% |
| Valuation | |||||
| P/B | — | — | — | 225.49 | 278.33 |
| Growth & Yield | |||||
| EPS Growth | — | — | -64.8% | -208.9% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-99.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.95 → n/d
Residual
-99.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.